- Home
- PRME vs VEL Comparison
PRME vs VEL Comparison
Compare PRME & VEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRME | VEL |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 765.5M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRME | VEL |
|---|---|---|
| Price | $3.54 | $17.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.56 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.5M | 63.2K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 43.98 |
| EPS | N/A | ★ 0.57 |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | $6.01 |
| Revenue Next Year | $47.01 | $19.02 |
| P/E Ratio | ★ N/A | $31.04 |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.18 | $16.19 |
| 52 Week High | $6.94 | $21.40 |
Technical Indicators
Market Signals| Indicator | PRME | VEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 43.10 |
| Support Level | $3.15 | $16.83 |
| Resistance Level | $3.60 | $19.17 |
| Average True Range (ATR) | 0.23 | 0.55 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 93.44 | 58.78 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.